Drug Trial Radar · NCT03393884
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 5, 2018
Primary completion
Jul 25, 2024
Study completion May 30, 2026
Sponsor
- Lead sponsor
- ImunonIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
IMNN-001Biological
IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
CarboplatinDrug
AUC 6 IV over 1 hour on Day 1 of each cycle
PaclitaxelDrug
175 mg/m2 IV over 3 hours on Day 1 of each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Mitchell Cancer Institute (University of South Alabama)
Mobile, Alabama
Gynecologic Oncology Associates (Hoag Hospital)
Newport Beach, California
Innovative Clinical Research
Whittier, California
Advent Health
Orlando, Florida
Women's Care Florida
St. Petersburg, Florida
Massachusetts General Hospital
Boston, Massachusetts
Washington University School of Medicine in St. Louis
St Louis, Missouri
MD Anderson at Cooper
Camden, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
Monter Cancer Center
Lake Success, New York
NYU Langone, Long Island
Mineola, New York
NYU Langone
New York, New York
Stephenson Cancer Center - Oklahoma University
Oklahoma City, Oklahoma
Providence Cancer Institute
Portland, Oregon
Sanford Health
Sioux Falls, South Dakota
Chattanooga Women's Health
Chattanooga, Tennessee
The West Clinic
Germantown, Tennessee
Providence Health Care
Spokane, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
CHUM
Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.